Century Therapeutics, INC Form 4 insider transactions

Adrienne Farid, Chief Operations Officer of Century Therapeutics, reports the sale of shares to cover tax obligations and the grant of restricted stock units and stock options.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, reports the sale of shares to cover tax obligations and the grant of restricted stock units.

Century Therapeutics' CEO, Brent Pfeiffenberger, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Adrienne Farid, Chief Operations Officer of Century Therapeutics, sold 1,054 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 351 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Century Therapeutics CEO, Brent Pfeiffenberger, sold 243,447 shares of common stock to cover tax obligations related to vesting restricted stock units.

Adrienne Farid, Chief Operations Officer of Century Therapeutics, sold 1,033 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Douglas Carr, SVP of Finance & Operations at Century Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Morgan Conn, CFO of Century Therapeutics, Inc., reports the acquisition of stock options and restricted stock units.

Chad Cowan, Chief Scientific Officer of Century Therapeutics, Inc., reports the acquisition of stock options and restricted stock units.

Director Quimi Daphne acquired 5,000 shares of Century Therapeutics (IPSC) at an average price of $1.5314 on September 12, 2024.

Adrienne Farid, Chief Operations Officer of Century Therapeutics, sold 1,073 shares of common stock on August 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Douglas Carr, SVP of Finance & Operations at Century Therapeutics, sold 289 shares of common stock on August 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 586 shares of common stock at $2.50 per share on July 26, 2024, under a pre-arranged 10b5-1 trading plan.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold shares of common stock on July 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock on June 20, 2024, under a pre-arranged 10b5-1 trading plan.

Joseph Jimenez, a director at Century Therapeutics, acquired 44,000 stock options on June 20, 2024, according to a Form 4 filing with the SEC.

Timothy Walbert, a director at Century Therapeutics, acquired 44,000 stock options at an exercise price of $2.69 on June 20, 2024.

Daphne Quimi, a director at Century Therapeutics, Inc., acquired stock options exercisable for 44,000 shares of common stock.

Cynthia Butitta, a director at Century Therapeutics, acquired stock options exercisable for 44,000 shares of common stock.

Alessandro Riva, a director at Century Therapeutics, acquired 44,000 stock options on June 20, 2024, according to a recent SEC Form 4 filing.

Carlo Rizzuto, a director at Century Therapeutics, Inc., acquired stock options for 44,000 shares on June 20, 2024.

Kimberly Blackwell, a director at Century Therapeutics, acquired stock options for 44,000 shares of common stock on June 20, 2024.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, reports the acquisition of 17,007 restricted stock units (RSUs) on June 7, 2024.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock at an average price of $2.9978 under a pre-arranged trading plan.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock at an average price of $2.9955 under a pre-arranged trading plan.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock on May 6, 2024, under a pre-arranged 10b5-1 trading plan.

Douglas Carr, SVP of Finance & Operations at Century Therapeutics, sold 257 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Adrienne Farid, Chief Operations Officer of Century Therapeutics, sold 913 shares of common stock on May 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock at an average price of $3.0979 under a pre-arranged trading plan.